초록 열기/닫기 버튼
Purpose: To evaluate the efficacy of focal verteporfin photodynamic therapy (PDT) in patients diagnosed withchronic central serous chorioretinopathy (CSC). Methods: This study enrolled 52 eyes of 52 patients with chronic CSC who had received verteporfin PDT. Thelaser spot size of 26 eyes covering only the localized hyperfluorescent area in indocyanine green angiographywas classified as focal PDT. The PDT spot size of the other 26 eyes covered the total area of retinal pigmentepithelial detachment including the leaking point and was defined as conventional PDT. The central subfieldthickness and subfoveal choroidal thickness were measured using Heidelberg Spectralis optical coherencetomography before PDT and at months 1, 3, 6, and 12 after PDT. Results: The mean spot size of the PDT was 1,995 μm in the focal group and 2,995 μm in the conventionalgroup. Central subfield thickness steadily decreased in both groups. The mean baseline subfoveal choroidalthickness for the two groups was 334.95 and 348.35 μm, respectively, with no significant difference (p = 0.602). Subfoveal choroidal thickness decreased significantly to 304.20 μm at 1 month, 284.85 μm at 3 months,271.60 μm at 6 months, and 265.95 μm at 12 months in the focal group (p < 0.001, p < 0.001, p < 0.001, andp < 0.001, respectively, compared with baseline). In the conventional group, subfoveal choroidal thicknessdecreased significantly to 318.75, 300, 284, and 272 μm at 1, 3, 6, and 12 months, respectively (p < 0.001,p < 0.001, p < 0.001 and p < 0.001 compared with baseline). There were no significant differences betweenthe two groups in subfoveal choroidal thickness based on PDT spot size at 1, 3, 6, and 12 months (p = 0.633,p = 0.625, p = 0.676, and p =0.755, respectively). Conclusions: Focal verteporfin PDT for CSC significantly decreased the subretinal fluid and sufoveal choroidalthickness to the same extent as conventional PDT.
